IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-45221-2.html
   My bibliography  Save this article

CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes

Author

Listed:
  • Sameeha Jilani

    (David Geffen School of Medicine at the University of California Los Angeles (UCLA))

  • Justin D. Saco

    (David Geffen School of Medicine at the University of California Los Angeles (UCLA))

  • Edurne Mugarza

    (David Geffen School of Medicine at the University of California Los Angeles (UCLA))

  • Aleida Pujol-Morcillo

    (David Geffen School of Medicine at the University of California Los Angeles (UCLA))

  • Jeffrey Chokry

    (David Geffen School of Medicine at the University of California Los Angeles (UCLA))

  • Clement Ng

    (David Geffen School of Medicine at the University of California Los Angeles (UCLA))

  • Gabriel Abril-Rodriguez

    (David Geffen School of Medicine at the University of California Los Angeles (UCLA)
    Parker Institute for Cancer Immunotherapy Center at UCLA)

  • David Berger-Manerio

    (David Geffen School of Medicine at the University of California Los Angeles (UCLA))

  • Ami Pant

    (David Geffen School of Medicine at UCLA)

  • Jane Hu

    (David Geffen School of Medicine at UCLA)

  • Rubi Gupta

    (David Geffen School of Medicine at the University of California Los Angeles (UCLA))

  • Agustin Vega-Crespo

    (David Geffen School of Medicine at the University of California Los Angeles (UCLA))

  • Ignacio Baselga-Carretero

    (David Geffen School of Medicine at the University of California Los Angeles (UCLA))

  • Jia M. Chen

    (David Geffen School of Medicine at the University of California Los Angeles (UCLA)
    Parker Institute for Cancer Immunotherapy Center at UCLA)

  • Daniel Sanghoon Shin

    (VA Greater Los Angeles Healthcare System
    UCLA
    Jonsson Comprehensive Cancer Center—UCLA)

  • Philip Scumpia

    (UCLA
    VA Greater Los Angeles Healthcare System-West Los Angeles)

  • Roxana A. Radu

    (David Geffen School of Medicine at UCLA)

  • Yvonne Chen

    (Parker Institute for Cancer Immunotherapy Center at UCLA
    Jonsson Comprehensive Cancer Center—UCLA
    Immunology, and Molecular Genetics at UCLA
    Broad Stem Cell Research Center—UCLA)

  • Antoni Ribas

    (David Geffen School of Medicine at the University of California Los Angeles (UCLA)
    Parker Institute for Cancer Immunotherapy Center at UCLA
    Jonsson Comprehensive Cancer Center—UCLA
    Broad Stem Cell Research Center—UCLA)

  • Cristina Puig-Saus

    (David Geffen School of Medicine at the University of California Los Angeles (UCLA)
    Parker Institute for Cancer Immunotherapy Center at UCLA
    Jonsson Comprehensive Cancer Center—UCLA
    Broad Stem Cell Research Center—UCLA)

Abstract

A major limitation to developing chimeric antigen receptor (CAR)-T cell therapies for solid tumors is identifying surface proteins highly expressed in tumors but not in normal tissues. Here, we identify Tyrosinase Related Protein 1 (TYRP1) as a CAR-T cell therapy target to treat patients with cutaneous and rare melanoma subtypes unresponsive to immune checkpoint blockade. TYRP1 is primarily located intracellularly in the melanosomes, with a small fraction being trafficked to the cell surface via vesicular transport. We develop a highly sensitive CAR-T cell therapy that detects surface TYRP1 in tumor cells with high TYRP1 overexpression and presents antitumor activity in vitro and in vivo in murine and patient-derived cutaneous, acral and uveal melanoma models. Furthermore, no systemic or off-tumor severe toxicities are observed in an immunocompetent murine model. The efficacy and safety profile of the TYRP1 CAR-T cell therapy supports the ongoing preparation of a phase I clinical trial.

Suggested Citation

  • Sameeha Jilani & Justin D. Saco & Edurne Mugarza & Aleida Pujol-Morcillo & Jeffrey Chokry & Clement Ng & Gabriel Abril-Rodriguez & David Berger-Manerio & Ami Pant & Jane Hu & Rubi Gupta & Agustin Vega, 2024. "CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-45221-2
    DOI: 10.1038/s41467-024-45221-2
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-45221-2
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-45221-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Louai Labanieh & Crystal L. Mackall, 2023. "CAR immune cells: design principles, resistance and the next generation," Nature, Nature, vol. 614(7949), pages 635-648, February.
    2. Robbie G. Majzner & Sneha Ramakrishna & Kristen W. Yeom & Shabnum Patel & Harshini Chinnasamy & Liora M. Schultz & Rebecca M. Richards & Li Jiang & Valentin Barsan & Rebecca Mancusi & Anna C. Geraghty, 2022. "GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas," Nature, Nature, vol. 603(7903), pages 934-941, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Guillem Pascual-Pasto & Brendan McIntyre & Margaret G. Hines & Anna M. Giudice & Laura Garcia-Gerique & Jennifer Hoffmann & Pamela Mishra & Stephanie Matlaga & Simona Lombardi & Rawan Shraim & Patrick, 2024. "CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    2. Rocío Castellanos-Rueda & Raphaël B. Roberto & Florian Bieberich & Fabrice S. Schlatter & Darya Palianina & Oanh T. P. Nguyen & Edo Kapetanovic & Heinz Läubli & Andreas Hierlemann & Nina Khanna & Sai , 2022. "speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    3. Irene Andreu-Saumell & Alba Rodriguez-Garcia & Vanessa Mühlgrabner & Marta Gimenez-Alejandre & Berta Marzal & Joan Castellsagué & Fara Brasó-Maristany & Hugo Calderon & Laura Angelats & Salut Colell &, 2024. "CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    4. Derek Lee & Zachary Spencer Dunn & Wenbin Guo & Carl J. Rosenthal & Natalie E. Penn & Yanqi Yu & Kuangyi Zhou & Zhe Li & Feiyang Ma & Miao Li & Tsun-Ching Song & Xinjian Cen & Yan-Ruide Li & Jin J. Zh, 2023. "Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering," Nature Communications, Nature, vol. 14(1), pages 1-19, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-45221-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.